Servier selects third cardiovascular target triggering the first milestone under the collaboration
SURESNES, France, and BOULDER, Colo., May 23, 2013 – Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise in the development of treatments for cardiovascular diseases, and miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that Servier has elected to add a new target as part of its existing agreement for advancing the research, development and commercialization of microRNA-based drug candidates for the treatment of cardiovascular disease. With this selection, Servier and miRagen now have three microRNA programs under development.
“Our selection of a third target is indicative of the strength of our partnership with miRagen, as well as our shared commitment to develop microRNA-based therapies for the treatment of cardiovascular disease,” said Dr. Jean-Paul Vilaine, Head of Servier’s Cardiovascular Research Unit. “We look forward to our continued collaboration to advance promising drug candidates.”
For Dr. Jean-Philippe Seta, Chief Executive Officer of Servier, “Micro-RNA is now the gateway to acting at the deepest level of gene expression regulation, with exciting [click to continue…]
Incoming search terms for this article:
miRagen Therapeutics, Inc. Exclusively Licenses Intellectual Property from the University of Glasgow for microRNA-145
IP generated as a result of collaboration between researchers from miRagen, the University of Glasgow and the University of Cambridge
BOULDER, Colo., Mar 05, 2013 (BUSINESS WIRE) — –Preliminary results in pre-clinical models show significant promise in treatment of a disease with very high unmet medical need
miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics, and the University of Glasgow, a world-leader in cardiovascular research, announced today that they have signed an exclusive license agreement for intellectual property they developed as part of an ongoing collaboration for microRNA-145 in pulmonary arterial hypertension (PAH). This licensing agreement provides miRagen with exclusive rights to an important discovery made in collaboration with the University of Glasgow and the University of Cambridge, enabling miRagen to advance miR-145 inhibition as a potential therapeutic approach for PAH.
PAH is a devastating, progressive disease driven by abnormal cellular proliferation and obstruction of small blood vessels in the lung, resulting in elevated pulmonary arterial pressure and, ultimately, fatal right-sided heart failure. Existing vasodilator therapies do not adequately address the fundamental disease mechanisms, a fact highlighted by high mortality rates. The median period of survival after diagnosis, based [click to continue…]
HOERSHOLM, Denmark and BOULDER, Colo., Jan. 8, 2013 /PRNewswire/ — Santaris Pharma A/S and miRagen Therapeutics, Inc. today announced that they have expanded their existing partnership in the field of microRNA therapeutics.
Under the expanded agreement, miRagen obtains a broad non-exclusive license in the miRNA therapeutics field for therapeutics research and world-wide exclusive rights to research, develop and commercialize LNA drugs against up to six additional microRNA targets that have been shown to be important in human disease areas of high unmet need. This brings the total number of microRNA targets under the agreement to ten. Santaris Pharma A/S will receive a combination of cash and equity in consideration for the licenses as well as clinical milestones and royalties on products emerging from the alliance. Financial terms were not disclosed.
Henrik Oerum, CSO and VP, Business Development at Santaris Pharma A/S stated: “Our collaboration with miRagen is an important part of our corporate strategy in the microRNA therapeutics field, so we are very [click to continue…]
LONDON, January 9, 2012/PRNewswire-FirstCall/ —
– Third collaboration to investigate the potential application of Silence’s proprietary RNAi delivery technologies in the development of novel microRNA-based therapeutics
Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc. (“miRagen”), to assess the delivery potential of Silence’s proprietary DBTC delivery system with miRagen’s novel microRNA- (miRNA-) based therapeutics. MiRagen is a pre-clinical stage biopharmaceutical company founded to develop innovative miRNA-based therapeutics for the treatment of cardiovascular and muscle disease.
Under the terms of the agreement, miRagen will provide Silence with specific miRNA sequences, which Silence will formulate with its proprietary DBTC delivery system in order to develop multiple candidate drugs. MiRagen will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. Financial terms of the collaboration are not disclosed.
DBTC is a proprietary RNAi delivery system developed by Silence. It is a novel lipid-based formulation that functionally delivers short interfering RNA (siRNA) to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.
Thomas Christely, Chief Executive Officer of Silence Therapeutics, said: “We are delighted to be collaborating with miRagen. This is the third collaboration that [click to continue…]